Retrieve available abstracts of 129 articles: HTML format
Single Articles
June 2025
SPOSATO LA, Ayan D, Ahmed M, Fridman S, et al Extended CT angiography versus standard CT angiography for the detection of
cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic
attack (DAYLIGHT): a prospective, randomised, open-label, blinded end-point
trial.
Lancet Neurol. 2025;24:489-499. PubMedAbstract available
MANLEY GT, Dams-O'Connor K, Alosco ML, Awwad HO, et al A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI
Classification and Nomenclature Initiative.
Lancet Neurol. 2025;24:512-523. PubMedAbstract available
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS
Platform Trial): an adaptive, phase 2/3, double-blind, randomised,
placebo-controlled trial.
Lancet Neurol. 2025;24:500-511. PubMedAbstract available
MARSAN E, Gutman D, Hohman TJ, Phatak M, et al The Path-NeuroDegeneration consortium.
Lancet Neurol. 2025;24:482. PubMed
NOGUEIRA RG, Bhatt N, Haussen DC, Moehlenbruch MA, et al Endovascular treatment of distal arterial occlusions: a more distant reality than
ever?
Lancet Neurol. 2025;24:478-480. PubMed
GARCIA-ESPERON C, Parsons MW Shedding DAYLIGHT on atrial thrombus in hyperacute stroke.
Lancet Neurol. 2025;24:472-473. PubMed
May 2025
DONNERS SJA, van Velzen TJ, Cheng SF, Gregson J, et al Optimised medical therapy alone versus optimised medical therapy plus
revascularisation for asymptomatic or low-to-intermediate risk symptomatic
carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised
trial.
Lancet Neurol. 2025;24:389-399. PubMedAbstract available
HO JK, Hankey GJ Carotid revascularisation for carotid stenosis.
Lancet Neurol. 2025;24:372-373. PubMed
April 2025
CAVALCANTE F, Treurniet K, Kaesmacher J, Kappelhof M, et al Intravenous thrombolysis before endovascular treatment versus endovascular
treatment alone for patients with large vessel occlusion and carotid tandem
lesions: individual participant data meta-analysis of six randomised trials.
Lancet Neurol. 2025;24:305-315. PubMedAbstract available
SCHLAUG G, Cassarly C, Feld JA, Wolf SL, et al Safety and efficacy of transcranial direct current stimulation in addition to
constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2):
a phase 2, multicentre, randomised, sham-controlled triple-blind trial.
Lancet Neurol. 2025 Mar 26:S1474-4422(25)00044. PubMedAbstract available
MIZIELINSKA S, Hautbergue GM, Gendron TF, van Blitterswijk M, et al Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in
C9orf72: from genetics to therapeutics.
Lancet Neurol. 2025;24:261-274. PubMedAbstract available
VAN DE MUNCKHOF A, van Kammen MS, Tatlisumak T, Krzywicka K, et al Direct oral anticoagulants versus vitamin K antagonists for cerebral venous
thrombosis (DOAC-CVT): an international, prospective, observational cohort study.
Lancet Neurol. 2025;24:199-207. PubMedAbstract available
February 2025
PRICE C Neuroprotection in acute ischaemic stroke: reasons for optimism?
Lancet Neurol. 2025 Feb 4:S1474-4422(25)00007. PubMed
TYMIANSKI M, Hill MD, Goyal M, Christenson J, et al Safety and efficacy of nerinetide in patients with acute ischaemic stroke
enrolled in the early window: a post-hoc meta-analysis of individual patient data
from three randomised trials.
Lancet Neurol. 2025 Feb 4:S1474-4422(24)00515. PubMedAbstract available
SHOAMANESH A, Field TS, Coutts SB, Sharma M, et al Apixaban versus aspirin for stroke prevention in people with subclinical atrial
fibrillation and a history of stroke or transient ischaemic attack: subgroup
analysis of the ARTESiA randomised controlled trial.
Lancet Neurol. 2025;24:140-151. PubMedAbstract available
LIU R, Zhao J, Rudd AG From stroke awareness to stroke action awareness.
Lancet Neurol. 2025;24:96. PubMed
SPOSATO LA, Wachter R Anticoagulation for patients with device-detected atrial fibrillation and a
history of stroke.
Lancet Neurol. 2025;24:92-94. PubMed
MOENS TG, Da Cruz S, Neumann M, Shelkovnikova TA, et al Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad
implications.
Lancet Neurol. 2025;24:166-178. PubMedAbstract available
COLEMAN KKL, Berry S, Cummings J, Hsiung GR, et al Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a
multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover,
phase 2a/2b superiority trial.
Lancet Neurol. 2025;24:128-139. PubMedAbstract available
HABIB AA, Zhao C, Aban I, Franca MC Jr, et al Safety and efficacy of satralizumab in patients with generalised myasthenia
gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled
phase 3 trial.
Lancet Neurol. 2025;24:117-127. PubMedAbstract available
ANTOZZI C, Vu T, Ramchandren S, Nowak RJ, et al Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis
(Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Lancet Neurol. 2025;24:105-116. PubMedAbstract available
January 2025
YANG P, Zhang Y, Liu J Ischaemic stroke in 2024: progress on multiple fronts.
Lancet Neurol. 2025;24:7-8. PubMed
December 2024
GETTINGS JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, et al Diagnosis and management of status epilepticus: improving the status quo.
Lancet Neurol. 2024 Dec 2:S1474-4422(24)00430. PubMedAbstract available
SHETH KN, Albers GW, Saver JL, Campbell BCV, et al Intravenous glibenclamide for cerebral oedema after large hemispheric stroke
(CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
Lancet Neurol. 2024;23:1205-1213. PubMedAbstract available
LIU Q, Mo S, Wu J, Tong X, et al Safety and efficacy of early versus delayed acetylsalicylic acid after surgery
for spontaneous intracerebral haemorrhage in China (E-start): a prospective,
multicentre, open-label, blinded-endpoint, randomised trial.
Lancet Neurol. 2024;23:1195-1204. PubMedAbstract available
November 2024
TURC G, Nguyen TN Reconsidering prourokinase for acute ischaemic stroke.
Lancet Neurol. 2024 Nov 28:S1474-4422(24)00474. PubMed
LI S, Gu HQ, Feng B, Li H, et al Safety and efficacy of intravenous recombinant human prourokinase for acute
ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3,
open-label, non-inferiority, randomised controlled trial.
Lancet Neurol. 2024 Nov 28:S1474-4422(24)00436. PubMedAbstract available
KRUYT ND, Nederkoorn PJ, Sandset EC, Lyden P, et al A cautionary view on blood pressure lowering in patients with acute ischaemic
stroke receiving reperfusion therapy.
Lancet Neurol. 2024 Nov 25:S1474-4422(24)00438. PubMed
MUIR KW, Ford GA, Ford I, Wardlaw JM, et al Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2):
a randomised, parallel group, open-label trial.
Lancet Neurol. 2024;23:1087-1096. PubMedAbstract available
BRALEY TJ, Ehde DM, Alschuler KN, Little R, et al Comparative effectiveness of cognitive behavioural therapy, modafinil, and their
combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised,
statistician-blinded, parallel-arm trial.
Lancet Neurol. 2024;23:1108-1118. PubMedAbstract available
PALAIODIMOU L, Tsivgoulis G A new standard for thrombolysis in acute ischaemic stroke.
Lancet Neurol. 2024;23:1064-1065. PubMed
October 2024
LIM SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, et al Uncovering the genetic basis of Parkinson's disease globally: from discoveries to
the clinic.
Lancet Neurol. 2024 Oct 21:S1474-4422(24)00378. PubMedAbstract available
VOLOVICI V, Cenzato M, Meling TR The European expertise network for open microvascular surgery.
Lancet Neurol. 2024 Oct 11:S1474-4422(24)00409. PubMed
Global, regional, and national burden of stroke and its risk factors, 1990-2021:
a systematic analysis for the Global Burden of Disease Study 2021.
Lancet Neurol. 2024;23:973-1003. PubMedAbstract available
WU S, Liu M Global burden of stroke: dynamic estimates to inform action.
Lancet Neurol. 2024;23:952-953. PubMed
AMEZCUA L, Rotstein D, Shirani A, Ciccarelli O, et al Differential diagnosis of suspected multiple sclerosis: considerations in people
from minority ethnic and racial backgrounds in North America, northern Europe,
and Australasia.
Lancet Neurol. 2024;23:1050-1062. PubMedAbstract available
CORREALE J, Solomon AJ, Cohen JA, Banwell BL, et al Differential diagnosis of suspected multiple sclerosis: global health
considerations.
Lancet Neurol. 2024;23:1035-1049. PubMedAbstract available
September 2024
CANEVELLI M, Jackson-Tarlton C, Rockwood K Frailty for neurologists: perspectives on how frailty influences care planning.
Lancet Neurol. 2024 Sep 11:S1474-4422(24)00291. PubMedAbstract available
OSPEL JM, Ganesh A, Goyal M Pragmatic outcomes for stroke research.
Lancet Neurol. 2024;23:860-862. PubMed
YOGENDRAKUMAR V, Lin L, Medcalf RL, Parsons MW, et al Improving thrombolysis efficiency for acute ischaemic stroke.
Lancet Neurol. 2024;23:853-855. PubMed
August 2024
LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al Dietary intervention for post-stroke dysphagia - Authors' reply.
Lancet Neurol. 2024;23:764-765. PubMed
SHIMIZU A, Yamaguchi K, Kunieda K, Ohno T, et al Dietary intervention for post-stroke dysphagia.
Lancet Neurol. 2024;23:763-764. PubMed
THE LANCET NEUROLOGY A real chance to reduce death and disability from stroke.
Lancet Neurol. 2024;23:749. PubMed
July 2024
MORIMOTO T, Sakakibara F Endovascular thrombectomy for large ischaemic stroke: outcomes beyond 90 days.
Lancet Neurol. 2024 Jul 26:S1474-4422(24)00290. PubMed
THOMALLA G, Fiehler J, Subtil F, Bonekamp S, et al Endovascular thrombectomy for acute ischaemic stroke with established large
infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised
trial.
Lancet Neurol. 2024 Jul 26:S1474-4422(24)00278. PubMedAbstract available
SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant
Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly
Inherited Alzheimer Network observational study (DIAN-OBS).
Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236. PubMedAbstract available
BOURCIER R, Marnat G, Dargazanli C, Zhu F, et al Safety and efficacy of stent retrievers plus contact aspiration in patients with
acute ischaemic anterior circulation stroke and positive susceptibility vessel
sign in France (VECTOR): a randomised, single-blind trial.
Lancet Neurol. 2024;23:700-711. PubMedAbstract available
ABDALKADER M, Nguyen TN Susceptibility vessel sign and endovascular stroke therapy.
Lancet Neurol. 2024;23:653-654. PubMed
June 2024
GAO F, Tong X, Jia B, Wei M, et al Bailout intracranial angioplasty or stenting following thrombectomy for acute
large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label,
blinded-endpoint, randomised controlled trial.
Lancet Neurol. 2024 Jun 21:S1474-4422(24)00186. PubMedAbstract available
CAMPBELL BCV Durable benefit of thrombectomy 6-24 h after stroke onset.
Lancet Neurol. 2024 Jun 20:S1474-4422(24)00261. PubMed
HUIJBERTS I, Pinckaers FME, Olthuis SGH, van Kuijk SMJ, et al Collateral-based selection for endovascular treatment of acute ischaemic stroke
in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre,
open-label, randomised controlled trial in the Netherlands.
Lancet Neurol. 2024 Jun 20:S1474-4422(24)00228. PubMedAbstract available
PARSONS MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, et al Tenecteplase versus alteplase for thrombolysis in patients selected by use of
perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a
multicentre, randomised, controlled, phase 3 non-inferiority trial.
Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206. PubMedAbstract available
TOYODA K Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the
puzzle?
Lancet Neurol. 2024 Jun 13:S1474-4422(24)00258. PubMed
ALI M, van Etten ES, Akoudad S, Schaafsma JD, et al Haemorrhagic stroke and brain vascular malformations in women: risk factors and
clinical features.
Lancet Neurol. 2024;23:625-635. PubMedAbstract available
THE LANCET NEUROLOGY Forging ahead in haemorrhagic stroke research.
Lancet Neurol. 2024;23:545. PubMed
SISODIYA SM, Gulcebi MI, Fortunato F, Mills JD, et al Climate change and disorders of the nervous system.
Lancet Neurol. 2024;23:636-648. PubMedAbstract available
May 2024
OLAVARRIA VV Challenging the management of blood pressure before intravenous thrombolysis in
acute ischaemic stroke.
Lancet Neurol. 2024 May 15:S1474-4422(24)00208. PubMed
ZONNEVELD TP, Vermeer SE, van Zwet EW, Groot AED, et al Safety and efficacy of active blood-pressure reduction to the recommended
thresholds for intravenous thrombolysis in patients with acute ischaemic stroke
in the Netherlands (TRUTH): a prospective, observational, cluster-based,
parallel-group study.
Lancet Neurol. 2024 May 15:S1474-4422(24)00177. PubMedAbstract available
SARFO FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, et al The African Stroke Organization Conference 2023.
Lancet Neurol. 2024;23:459-460. PubMed
CORTESE I, Norato G, Harrington PR, Usher T, et al Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use
of JC virus DNA copy number in clinical trials.
Lancet Neurol. 2024;23:534-544. PubMedAbstract available
PELLINEN J, Foster EC, Wilmshurst JM, Zuberi SM, et al Improving epilepsy diagnosis across the lifespan: approaches and innovations.
Lancet Neurol. 2024;23:511-521. PubMedAbstract available
April 2024
YASSI N, Zhao H, Churilov L, Wu TY, et al Tranexamic acid versus placebo in individuals with intracerebral haemorrhage
treated within 2 h of symptom onset (STOP-MSU): an international, double-blind,
randomised, phase 2 trial.
Lancet Neurol. 2024 Apr 19:S1474-4422(24)00128. PubMedAbstract available
Medical management and surgery versus medical management alone for symptomatic
cerebral cavernous malformation (CARE): a feasibility study and randomised, open,
pragmatic, pilot phase trial.
Lancet Neurol. 2024 Apr 17:S1474-4422(24)00096. PubMedAbstract available
GUSTAVSSON EK, Follett J, Trinh J, Barodia SK, et al RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association,
and functional analyses.
Lancet Neurol. 2024 Apr 10:S1474-4422(24)00121. PubMedAbstract available
LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al Dysphagia after stroke: research advances in treatment interventions.
Lancet Neurol. 2024;23:418-428. PubMedAbstract available
SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al Secondary stroke prevention in people with atrial fibrillation: treatments and
trials.
Lancet Neurol. 2024;23:404-417. PubMedAbstract available
SPOSATO LA, Andrade JG, Field TS Detection of atrial fibrillation in patients after stroke - Authors' reply.
Lancet Neurol. 2024;23:336-337. PubMed
SIONTIS KC, Noseworthy PA, Friedman PA Detection of atrial fibrillation in patients after stroke.
Lancet Neurol. 2024;23:335-336. PubMed
KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al Pragmatic solutions for the global burden of stroke.
Lancet Neurol. 2024;23:334. PubMed
FEIGIN VL, Yaria J, Owolabi M Pragmatic solutions for the global burden of stroke - Authors' reply.
Lancet Neurol. 2024;23:334-335. PubMed
SCHLOGL M, Quinn TJ Pragmatic solutions for the global burden of stroke.
Lancet Neurol. 2024;23:333-334. PubMed
Global, regional, and national burden of disorders affecting the nervous system,
1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet Neurol. 2024;23:344-381. PubMedAbstract available
February 2024
MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic
stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a
trial.
Lancet Neurol. 2024;23:157-167. PubMedAbstract available
GANESH A Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute
ischaemic stroke.
Lancet Neurol. 2024;23:125-127. PubMed
SIMUNI T, Chahine LM, Poston K, Brumm M, et al A biological definition of neuronal alpha-synuclein disease: towards an integrated
staging system for research.
Lancet Neurol. 2024;23:178-190. PubMedAbstract available
CHAPLEAU M, La Joie R, Yong K, Agosta F, et al Demographic, clinical, biomarker, and neuropathological correlates of posterior
cortical atrophy: an international cohort study and individual participant data
meta-analysis.
Lancet Neurol. 2024;23:168-177. PubMedAbstract available
January 2024
SHARMA M, Molina CA, Toyoda K, Bereczki D, et al Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke
prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind,
placebo-controlled, dose-finding trial.
Lancet Neurol. 2024;23:46-59. PubMedAbstract available
KHATRI P Anticoagulants to prevent recurrent non-cardioembolic stroke.
Lancet Neurol. 2024;23:3-5. PubMed
ANDERSON CS Stroke advances in 2023: a new horizon for the management of intracerebral
haemorrhage.
Lancet Neurol. 2024;23:12-13. PubMed
December 2023
BRIGO F The (hi)story of stroke.
Lancet Neurol. 2023;22:1110. PubMed
UCHIYAMA S Anticoagulation in people with atrial fibrillation after intracranial
haemorrhage.
Lancet Neurol. 2023;22:1091-1092. PubMed
ABBOTT A, Schott L, Gao L, Budincevic H, et al Carotid artery overtreatment in the USA.
Lancet Neurol. 2023;22:1102-1103. PubMed
November 2023
KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al Effect of blood pressure-lowering agents on microvascular function in people with
small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised,
crossover trial.
Lancet Neurol. 2023;22:991-1004. PubMedAbstract available
RUBIANO AM, Lee K Traumatic brain injury research: homogenising heterogeneity.
Lancet Neurol. 2023;22:973-975. PubMed
ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al Hereditary transthyretin amyloid neuropathies: advances in pathophysiology,
biomarkers, and treatment.
Lancet Neurol. 2023;22:1061-1074. PubMedAbstract available
October 2023
MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al Digital mobility measures to predict Parkinson's disease.
Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376. PubMed
SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al Towards a new classification of atrial fibrillation detected after a stroke or a
transient ischaemic attack.
Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326. PubMedAbstract available
AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al Effects of oral anticoagulation in people with atrial fibrillation after
spontaneous intracranial haemorrhage (COCROACH): prospective, individual
participant data meta-analysis of randomised trials.
Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315. PubMedAbstract available
KAMEL H Reassessing the implications of atrial fibrillation detected after stroke.
Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406. PubMed
BRUSCA SB, Albert MA Balancing the scales of adversity: a socioecological approach to reducing the
global burden of stroke and cardiovascular disease.
Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386. PubMed
WATKINS DA Policy priorities for preventing stroke-related mortality and disability
worldwide.
Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387. PubMed
FEIGIN VL, Owolabi MO Pragmatic solutions to reduce the global burden of stroke: a World Stroke
Organization-Lancet Neurology Commission.
Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277. PubMed
MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
Lancet Neurol. 2023;22:946-958. PubMedAbstract available
IZZY S, Grashow R, Radmanesh F, Chen P, et al Long-term risk of cardiovascular disease after traumatic brain injury: screening
and prevention.
Lancet Neurol. 2023;22:959-970. PubMedAbstract available
September 2023
HUGGER SS, Do TP, Ashina H, Goicochea MT, et al Migraine in older adults.
Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206. PubMedAbstract available
LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al The assessment of dysphagia after stroke: state of the art and future directions.
Lancet Neurol. 2023;22:858-870. PubMedAbstract available
FENG W Diagnosis of post-stroke dysphagia: towards better treatment.
Lancet Neurol. 2023;22:778-779. PubMed
OSPEL JM, Goyal M Prehospital triage in acute stroke: which questions to ask?
Lancet Neurol. 2023;22:771-772. PubMed
D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid
genome sequencing in infantile epilepsy (Gene-STEPS): an international,
multicentre, pilot cohort study.
Lancet Neurol. 2023;22:812-825. PubMedAbstract available
GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al Prehospital screening of acute stroke with the National Institutes of Health
Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
Lancet Neurol. 2023;22:800-811. PubMedAbstract available
August 2023
ODDO M, Taccone FS, Petrosino M, Badenes R, et al The Neurological Pupil index for outcome prognostication in people with acute
brain injury (ORANGE): a prospective, observational, multicentre cohort study.
Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271. PubMedAbstract available
RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al Identification of genetic risk loci and causal insights associated with
Parkinson's disease in African and African admixed populations: a genome-wide
association study.
Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283. PubMedAbstract available
SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al Differential diagnosis of suspected multiple sclerosis: an updated consensus
approach.
Lancet Neurol. 2023;22:750-768. PubMedAbstract available
MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure
medications (MONEAD study) in the USA: a prospective, observational cohort study.
Lancet Neurol. 2023;22:712-722. PubMedAbstract available
MAYNARD G, Kannan R, Liu J, Wang W, et al Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical
spinal cord injury in the USA: a first-in-human and randomised clinical trial.
Lancet Neurol. 2023;22:672-684. PubMedAbstract available
GILADI N, Alcalay RN, Cutter G, Gasser T, et al Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an
international, multicentre, double-blind, randomised, placebo-controlled, phase 2
trial.
Lancet Neurol. 2023;22:661-671. PubMedAbstract available
July 2023
ENGLISH C, Ramage E Secondary stroke prevention: more questions than answers.
Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278. PubMed
SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al The structured ambulatory post-stroke care program for outpatient aftercare in
patients with ischaemic stroke in Germany (SANO): an open-label,
cluster-randomised controlled trial.
Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216. PubMedAbstract available
DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al Desmopressin for patients with spontaneous intracerebral haemorrhage taking
antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled,
multicentre feasibility trial.
Lancet Neurol. 2023;22:557-567. PubMedAbstract available
FRISONI GB, van der Flier W STRIVEing to describe small vessel disease.
Lancet Neurol. 2023;22:548-549. PubMed
GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell
therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label,
non-randomised phase 1b/2a study.
Lancet Neurol. 2023;22:578-590. PubMedAbstract available
CORBOY JR, Fox RJ, Kister I, Cutter GR, et al Risk of new disease activity in patients with multiple sclerosis who continue or
discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised,
single-blind, phase 4, non-inferiority trial.
Lancet Neurol. 2023;22:568-577. PubMedAbstract available
MEISEL A Are CAR T cells the answer to myasthenia gravis therapy?
Lancet Neurol. 2023;22:545-546. PubMed
June 2023
VAN DER MERWE J Stroke care quality-why recognition matters.
Lancet Neurol. 2023;22:471. PubMed
HAYWARD KS, Bernhardt J Aspiring to restore arm and hand function after stroke.
Lancet Neurol. 2023;22:464-465. PubMed
May 2023
DUERING M, Biessels GJ, Brodtmann A, Chen C, et al Neuroimaging standards for research into small vessel disease-advances since
2013.
Lancet Neurol. 2023 May 23:S1474-4422(23)00131. PubMedAbstract available
KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al Progression of cerebral amyloid angiopathy: a pathophysiological framework.
Lancet Neurol. 2023 May 23:S1474-4422(23)00114. PubMedAbstract available
HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis
(RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Neurol. 2023;22:395-406. PubMedAbstract available
BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al Safety and efficacy of rozanolixizumab in patients with generalised myasthenia
gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase
3 study.
Lancet Neurol. 2023;22:383-394. PubMedAbstract available
KASKI D, Koohi N, Haider S, Chandratheva A, et al The hyperacute vestibular syndrome: ear or brain?
Lancet Neurol. 2023;22:377-378. PubMed
April 2023
WU S, Anderson CS Antiplatelets for secondary stroke prevention in China.
Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130. PubMed
PAN Y, Meng X, Yuan B, Johnston SC, et al Indobufen versus aspirin in patients with acute ischaemic stroke in China
(INSURE): a randomised, double-blind, double-dummy, active control,
non-inferiority trial.
Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113. PubMedAbstract available
LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al Effect of atherosclerosis on 5-year risk of major vascular events in patients
with transient ischaemic attack or minor ischaemic stroke: an international
prospective cohort study.
Lancet Neurol. 2023;22:320-329. PubMedAbstract available
SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al Admission systolic blood pressure and effect of endovascular treatment in
patients with ischaemic stroke: an individual patient data meta-analysis.
Lancet Neurol. 2023;22:312-319. PubMedAbstract available
BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al The International Stroke Recovery and Rehabilitation Alliance.
Lancet Neurol. 2023;22:295-296. PubMed
MAZIGHI M The quest for optimal blood pressure management after stroke.
Lancet Neurol. 2023;22:285-286. PubMed
FEIGIN VL, Brainin M, Martins SCO The polypill from a public-health perspective.
Lancet Neurol. 2023;22:294-295. PubMed
March 2023
TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al Thrombolysis for acute ischaemic stroke: current status and future perspectives.
Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519. PubMedAbstract available